marimastat has been researched along with Brain Neoplasms in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (88.89) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baryshnikov, A; Borovjagin, AV; Cobbs, C; Kaverina, N; Lin, B; Schroeder, B; Shah, N; Ulasov, I | 1 |
| Berger, M; Chang, S; Devriendt, D; Kunwar, S; Lamborn, KR; Larson, DA; McDermott, MW; Nicholas, KM; Prados, M; Smith, V; Sneed, PK; Wara, WM | 1 |
| Newton, HB | 1 |
| Nakada, M | 1 |
| Sasaki, H; Yoshida, K | 1 |
| Takano, S | 1 |
| Baillet, M; Forsyth, PA; Fuller, GN; Levin, VA; Maestro, RD; Perry, JR; Phuphanich, S; Yung, WK | 1 |
| Aldape, KD; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Jaeckle, K; Levin, VA; Liu, V; Puduvalli, VK; Yung, WK | 1 |
| Groves, MD; Hess, KR; Jaeckle, KA; Levin, VA; Peterson, P; Puduvalli, VK; Yung, WK | 1 |
4 review(s) available for marimastat and Brain Neoplasms
| Article | Year |
|---|---|
Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Extracellular Matrix; Gene Expression Profiling; Humans; Hydroxamic Acids; Matrix Metalloproteinases; Neoplasm Invasiveness; Quality of Life; Serine Endopeptidases; Survival | 2004 |
[Role of extracellular matrix degradation enzyme for glioma invasion].
Topics: ADAM Proteins; Brain Neoplasms; Dacarbazine; Drug Design; Enzyme Inhibitors; Extracellular Matrix; Glioma; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Serine Endopeptidases; Temozolomide; Tetracyclines | 2005 |
[Inhibition of cellular adhesion and invasion in gliomas].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cathepsin B; Cell Adhesion; Clinical Trials as Topic; Drug Design; Extracellular Matrix; Glioma; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydroxamic Acids; Integrins; Laminin; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Multigene Family; Neoplasm Invasiveness; Signal Transduction; Snake Venoms; Urokinase-Type Plasminogen Activator | 2005 |
[Anti-angiogenesis treatment for brain tumors--present and future].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Depression, Chemical; Fibroblast Growth Factors; Glioma; Humans; Hydroxamic Acids; Metalloproteases; Neovascularization, Pathologic; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Retinoids; Suramin; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2005 |
4 trial(s) available for marimastat and Brain Neoplasms
| Article | Year |
|---|---|
Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Radiation; Enzyme Inhibitors; Female; Follow-Up Studies; Glioma; Humans; Hydroxamic Acids; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Radiosurgery; Recurrence; Time Factors; Treatment Outcome | 2002 |
Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Double-Blind Method; Enzyme Inhibitors; Female; Glioblastoma; Gliosarcoma; Humans; Hydroxamic Acids; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Musculoskeletal Diseases; Quality of Life; Survival Analysis; Treatment Failure | 2006 |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 Enzyme System; Dacarbazine; Disease-Free Survival; Enzyme Inhibitors; Glioma; Humans; Hydroxamic Acids; Joint Diseases; Joints; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2002 |
1 other study(ies) available for marimastat and Brain Neoplasms
| Article | Year |
|---|---|
MT1-MMP silencing by an shRNA-armed glioma-targeted conditionally replicative adenovirus (CRAd) improves its anti-glioma efficacy in vitro and in vivo.
Topics: Adenoviridae; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Glioma; Humans; Hydroxamic Acids; Interleukin-8; Male; Matrix Metalloproteinase 14; Mice; Middle Aged; Neoplasm Transplantation; Neovascularization, Pathologic; Oncolytic Virotherapy; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2015 |